Intellia Therapeutics, Inc. NTLA NASDAQ

Intellia Therapeutics, Inc. (NTLA) reported total assets of $842.13M and total liabilities of $170.73M for fiscal year 2025, resulting in total equity of $671.39M.

The company held $449.88M in cash and short-term investments. Total debt stood at $93.33M, with net debt of $-62.14M. The Debt-to-Equity (D/E) ratio was 0.14 (conservative).

Current ratio is 5.08, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.14, current ratio of 5.08 — balance sheet is strong
• MOAT (47/100) — Total assets $842.13M and equity $671.39M support the company's competitive scale
• VALUE (96/100) — Debt-to-Equity 0.14 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 57/100 with 4/7 criteria passed.

VRTX

Vertex Pharmaceuticals Incorporated

$444.28

+0.96%

CRSP

CRISPR Therapeutics AG

$56.86

+3.70%

BEAM

Beam Therapeutics Inc.

$30.30

+0.40%

VERV

Verve Therapeutics, Inc.

$11.13

+0.27%

SANA

Sana Biotechnology, Inc.

$3.48

+8.41%

PRME

Prime Medicine, Inc.

$3.70

+1.09%

DNA

Ginkgo Bioworks Holdings, Inc.

$7.72

+15.57%

EDIT

Editas Medicine, Inc.

$3.39

+5.94%